Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases

Yao, Qiong; Zhang, Xiuyuan; Chen, Dajin

doi:10.3389/fonc.2022.848296

Cited by 10 publications

(11 citation statements)

References 176 publications

(255 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 36 FOXD3‐AS1 is strongly expressed in a range of disorders, including breast cancer, nasopharyngeal carcinoma, osteosarcoma, melanoma, and thyroid cancer. 37 Zheng et al 38 found that knocking down FOXD3‐AS1 prevented hypoxia‐induced cardiomyocyte damage by up‐regulating the cardioprotective molecule miR‐150‐5p. SLCO4A1‐AS1 is a protective factor for HNSCC prognosis and is significantly associated with overall patient survival.…”

Section: Discussionmentioning

confidence: 99%

“…FOXD2‐AS1 is elevated in HNSCC tissues and is a potential predictor of HNSCC in patients, promoting the proliferation of HNSCC cell lines 36 . FOXD3‐AS1 is strongly expressed in a range of disorders, including breast cancer, nasopharyngeal carcinoma, osteosarcoma, melanoma, and thyroid cancer 37 . Zheng et al 38 found that knocking down FOXD3‐AS1 prevented hypoxia‐induced cardiomyocyte damage by up‐regulating the cardioprotective molecule miR‐150‐5p.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A hypoxia‐related lncRNA model for prediction of head and neck squamous cell carcinoma prognosis

Xiang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Head and neck squamous cell carcinoma (HNSCC) is one of the most common and highly heterogeneous malignancies worldwide. Increasing studies have proven that hypoxia and related long non‐coding RNA (lncRNA) are involved in the occurrence and prognosis of HNSCC. The goal of this work is to construct a risk assessment model using hypoxia‐related lncRNAs (hrlncRNAs) for HNSCC prognosis prediction and personalized treatment. Methods Transcriptome expression matrix, clinical follow‐up data, and somatic mutation data of HNSCC patients were obtained from The Cancer Genome Atlas (TCGA). We used co‐expression analysis to identify hrlncRNAs, then screened for differentially expressed lncRNAs (DEhrlncRNAs), and paired these DEhrlncRNAs. The risk model was established through univariate, least absolute shrinkage and selection operator (LASSO), and stepwise multivariate Cox regression. Finally, we assessed the model from multiple perspectives of tumor mutation burden (TMB), tumor immune infiltration, chemotherapeutic sensitivity, immune checkpoint inhibitor (ICI), and functional enrichment. Results The risk assessment model included 14 hrlncRNA pairs. The risk score was observed to be a reliable prognostic factor. The high‐risk patients had an unfavorable prognosis and significant differences from the low‐risk group in TMB and tumor immune infiltration. In the high‐risk patients, the common immune checkpoints were down‐regulated, including CTLA4 and PDCD1, and the sensibility to paclitaxel and docetaxel was higher. The functional enrichment analysis suggested that the low‐risk group was accompanied by activated immune function. Conclusions The risk assessment model of 14‐hrlncRNA‐pairs demonstrated a promising prognostic prediction for HNSCC patients and can guide personalized clinical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A hypoxia‐related lncRNA model for prediction of head and neck squamous cell carcinoma prognosis

Xiang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…FOXD3-AS1 has been shown to have predictive value and functional roles in various diseases, including breast cancer, cervical cancer, nasopharyngeal carcinoma, cerebral ischemia/reperfusion injury, cardiomyocyte injury, allergic rhinitis, and so on [ 15 – 17 , 27 , 28 ]. Furthermore, FOXD3-AS1 has been found in nuclear or cytoplasm fractions, and its molecular mechanisms include acting as competing endogenous RNA [ 15 , 29 ], acting as mediators for gene promotor loci and histone modification factor interaction [ 19 ], stimulating proteins expression [ 20 ], interacting and sequestering proteins, and so on [ 14 , 18 ]. In this study, we found that FOXD3-AS1 was upregulated in all primary subtypes of LC at an early stage and increased as the disease progressed.…”

Section: Discussionmentioning

confidence: 99%

“…[15-17, 27, 28]. Furthermore, FOXD3-AS1 has been found in nuclear or cytoplasm fractions, and its molecular mechanisms include acting as competing endogenous RNA [15,29], acting as mediators for gene promotor loci and histone modification factor interaction [19], stimulating proteins expression [20], interacting and sequestering proteins, and so on [14,18]. In this study, we found that FOXD3-AS1 was upregulated in all primary subtypes of LC at an early stage and increased as the disease progressed.…”

Section: Discussionmentioning

confidence: 99%

“…LncRNA forkhead box D3 antisense 1 (FOXD3-AS1) is a 963 bp antisense transcript of the gene FOXD3, whose abnormal expression has been linked to pathophysiological characteristics of several diseases [14]. FOXD3-AS1, for example, affects the development of breast cancer, nasopharyngeal carcinoma, colon adenocarcinoma, and hepatocellular carcinoma via competing for the endogenous RNAs (ceRNAs) mechanism [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification

Liu¹,

Chen²,

Qi³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Purpose. Lung cancer (LC) is the most commonly diagnosed cancer and the leading cause of cancer-related deaths. More and more long noncoding RNA (lncRNA) are associated with cancer. This study aimed to assess whether plasma lncRNA could be used to diagnose early-stage LC and identify subtypes of LC. Methods. For bioinformatic analysis, we used genetic data from the Cancer Genome Atlas, lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC) datasets and a small cell lung cancer (SCLC) dataset from the Gene Expression Omnibus. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to examine the relative expression of lncRNA in LC tissues and plasma samples. The patients’ clinical information was obtained at the time of sample collection. Results. According to public datasets, the lncRNA forkhead box D3 antisense 1 (FOXD3-AS1) was significantly upregulated in LUAD, LUSC, and SCLC tissues over controls. RT-qPCR assays confirmed this finding in LUAD, LUSC, and SCLC tissues and plasma samples. Even early-stage receiver operating characteristic analysis showed that plasma FOXD3-AS1 could be used to discriminate LUAD, LUSC, and SCLC from normal controls and identify LC subtypes SCLC. Conclusion. FOXD3-AS1 is significantly upregulated in LC tissues and plasma. FOXD3-AS1 could be a potential biomarker for LC subtype identification and early diagnosis.

show abstract

Research on the mechanism of exosomes from different sources influencing the progression of lung cancer

Mao,

Liu

2024

Environmental Toxicology

View full text Add to dashboard Cite

As a key regulator of intercellular communication, exosomes are essential for tumor cells. In our study, we will explore the mechanisms of exosomes from different sources on lung cancer. We isolated CD8+T cells and cancer‐associated fibroblasts (CAFs) from venous blood and tumor tissues of lung cancer patients, and isolated exosomes. MiR‐2682 was high expression in CD8+T‐derived exosomes, and lncRNA‐FOXD3‐AS1 was upregulated in CAF‐derived exosomes. Online bioinformatics database analysis showed that RNA Binding Motif Protein 39 (RBM39) was identified as the target of miR‐2682, and eukaryotic translation initiation factors 3B (EIF3B) was identified as the RNA binding protein of FOXD3‐AS1. CD8+T‐derived exosomes inhibited the growth of A549 cells and promoted apoptosis, while miR‐2682 inhibits reversed these effects of CD8+T‐derived exosomes. CAF‐derived exosomes promoted the growth of A549 cells and inhibited apoptosis, while FOXD3‐AS1 siRNA reversed the effect of CAF‐derived exosomes. Mechanism studies have found that miR‐2682 inhibits the growth of lung cancer cells by inhibiting the expression of RBM39. FOXD3‐AS1 promoted the growth of lung cancer cells by binding to EIF3B. In vivo experiments showed that CD8+T cell‐derived exosome miR‐2682 inhibited lung cancer tumor formation, while CAF‐derived exosome FOXD3‐AS1 promoted lung cancer tumor formation. This study provides mechanistic insights into the role of miR‐2682 and FOXD3‐AS1 in lung cancer progression and provides new strategies for lung cancer treatment.

show abstract

Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases

Cited by 10 publications

References 176 publications

A hypoxia‐related lncRNA model for prediction of head and neck squamous cell carcinoma prognosis

A hypoxia‐related lncRNA model for prediction of head and neck squamous cell carcinoma prognosis

Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification

Research on the mechanism of exosomes from different sources influencing the progression of lung cancer

Contact Info

Product

Resources

About